Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
Status unconfirmed
Conditions studied: Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
In brief
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.
Key facts
- Study ID
- NCT05773196
- Run by
- Sanguine Biosciences
- People needed
- 5
- Starts
- 2023-03-14
- Expected to finish
- 2025-02-28
- Last updated by the study team
- 2024-04-18
Who can join
Age: 25 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sanguine Biosciences, Inc. — Woburn, Massachusetts, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.